New hope for stage 4 lung cancer: experimental combo therapy enters global trial

NCT ID NCT07365319

Recruiting now Disease control Sponsor: Eikon Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug (EIK1001) to standard immunotherapy and chemotherapy helps people with stage 4 non-small cell lung cancer live longer or slow tumor growth. About 750 adults whose cancer has spread will receive either the new combination or a placebo plus standard treatment. The goal is to see if the new drug improves survival and response rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE 4 NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER (SQUAMOUS OR NON SQUAMOUS) STAGE 4 NSCLC

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

NYU Langone Hospital Long Island
RECRUITING

Mineola, New York, 11501, United States
NYU Langone Hospital Manhattan
RECRUITING

New York, New York, 10016, United States
White Plains Hospital
RECRUITING

White Plains, New York, 10601, United States